Cefepime is a fourth-generation cephalosporin with a broad spectrum of in vitro activity \[[@CIT0001], [@CIT0002]\] that was first approved for clinical use in 1996 \[[@CIT0003]\]. Shortly afterwards, the US Food and Drug Administration (FDA) approved cefepime for the empiric treatment of febrile neutropenia, and cefepime is still recommended as a first-line option for this indication by organizations, such as the Infectious Diseases Society of America, the European Society for Medical Oncology, and the Japan Febrile Neutropenia Study Group \[[@CIT0004]\]. However, the safety and efficacy of cefepime therapy in febrile neutropenia has been controversial.

Specifically, between 2005 and 2010, a series of meta-analyses demonstrated increased overall mortality among patients receiving cefepime, both in and outside the setting of febrile neutropenia \[[@CIT0007]\]. Although a specific cause was never identified, serious concerns were raised, and the FDA (in cooperation with the manufacturer) conducted an extensive meta-analysis, including previously unpublished data, and concluded that cefepime administration was not associated with increased mortality \[[@CIT0003]\]. Nonetheless, another meta-analysis that was published shortly afterwards, and incorporated the mortality figures from the FDA review, again detected increased overall mortality among cefepime-treated patients with febrile neutropenia \[[@CIT0009]\]. Seven years have elapsed since then, but the controversy has yet to be resolved. The aim of the present meta-analysis was to reassess the efficacy and safety of cefepime in the management of febrile neutropenia and to investigate the impact of dosing regimens on outcomes, given the frequent use of low-dose (2 grams/12 hours, 100 mg/kg per day) cefepime therapy for this indication \[[@CIT0006], [@CIT0010]\].

MATERIALS AND METHODS {#s1}
=====================

The present study was designed and conducted in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guidelines \[[@CIT0013]\].

Data Sources and Search Strategy {#s2}
--------------------------------

We searched the PubMed and EMBASE databases as well as pertinent review articles and publicly available FDA records concerning the approval history of cefepime (<http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist>) to identify relevant studies. We also screened the references of all potentially eligible studies. The term (Cefepim\* OR BMY-28142 OR Maxipime OR Maxcef OR Cepimax OR Cepimex OR Axepim) AND (tumor OR cancer OR carcinoma OR sarcoma OR neoplasia OR malignancy OR leukemia OR leukaemia OR lymphoma OR oncolog\* OR hematolog\* OR haematolog\* OR neutropen\*) was used. We imposed no restrictions on publication dates, and the date of last access was November 28, 2016. We only considered studies published in English, French, German, or Spanish. Three authors (N.A., M.E.F., A.A.), working independently, retrieved the search results and screened the titles and abstracts for potentially eligible studies. Any discrepancies were resolved by team consensus. In cases of missing data, an attempt was made to contact the study authors. Conference proceedings were not considered.

Study Selection {#s3}
---------------

All randomized controlled trials reporting on the clinical efficacy of either (1) cefepime monotherapy versus alternative monotherapy or (2) cefepime plus aminoglycoside versus alternative monotherapy plus aminoglycoside (with the same aminoglycoside administered in both arms) in the setting of febrile neutropenia were eligible.

Outcomes of Interest, Data Extraction, and Quality Assessment {#s4}
-------------------------------------------------------------

Data on clinical efficacy (primary outcome) were extracted and analyzed. Consistent with previous studies \[[@CIT0007]\], clinical efficacy was defined as treatment success without therapy modification. If clinical efficacy was assessed at multiple time points, data from the time of last follow-up were included. In addition, similar to previous studies \[[@CIT0007]\], in cases where clinical efficacy was reported both as a percentage of evaluable patients (per-protocol) and of the modified intent-to-treat population, the latter analysis was used to limit the impact of crossover and dropout bias. In trials that were retrieved from FDA records, the modified intent-to-treat analysis conducted by the FDA medical officers was used. Our outcomes also included overall mortality (death from any cause at the time of the last follow-up), infection-specific mortality, treatment modification, superinfections, adverse events, toxicity-related treatment discontinuation, treatment failure in clinically documented infections, and microbiologically documented infections. Data on all reported adverse events were included in our analysis, irrespective of their presumed etiology. If an outcome was reported on both a per-protocol basis and as a percentage of the modified intent-to-treat population, the latter analysis was used. Studies were classified by geographic region according to the definitions used by the World Health Organization \[[@CIT0014]\]. We assessed the effect of cefepime administration on primary and secondary outcomes and performed subgroup analyses according to predetermined study characteristics, which included analyses of the cefepime dose used, the comparator regimens used (cefepime vs carbapenems, cefepime vs cephalosporins, cefepime vs penicillins), and the study quality metrics. Moreover, trials assessing cefepime monotherapy versus alternative monotherapy were examined separately from trials investigating combination therapies.

Study quality was assessed with the methodological approach described by the Cochrane Collaboration \[[@CIT0015]\]. Specifically, for each included study, 7 individual study characteristics (sequence generation, allocation concealment, blinding, outcome assessment, attrition bias, reporting bias, other bias) were rated as entailing a high, low, or unclear risk of bias. As such, each trial received 7 independent bias "ratings" and no cumulative indicator of study quality was calculated, in line with Cochrane recommendations \[[@CIT0015]\].

Data Synthesis and Statistical Analysis {#s5}
---------------------------------------

Given the minimal between-study heterogeneity (I^2^ \< 30.0%), a fixed-effects meta-analysis was conducted to estimate the pooled risk ratio (RR) and 95% confidence intervals (CIs) for each outcome \[[@CIT0007], [@CIT0016]\]. An RR \> 1 indicated a greater frequency of the respective outcome in the cefepime study arm. Publication bias was assessed with Egger's test (ET) and between-study heterogeneity with I^2^ \[[@CIT0017], [@CIT0018]\]. Data were excluded from our analysis if both treatment arms reported zero events for the examined outcome. Statistical analysis was performed with the STATA version 14 software package (StataCorp LP, College Station, TX), and statistical significance was defined as *P* ≤ .05.

RESULTS {#s6}
=======

Review Process, Quality Assessment, and General Study Characteristics {#s7}
---------------------------------------------------------------------

The review process is presented in [Figure 1](#F1){ref-type="fig"}. In brief, from the 2847 studies identified through our search, 30 trials fulfilled our inclusion criteria \[[@CIT0011], [@CIT0012], [@CIT0019]\]. Furthermore, our screening of article references, review articles, and FDA records yielded 2 additional trials \[[@CIT0047], [@CIT0048]\], as well as supplementary data from a previously identified study \[[@CIT0040]\]. Individual study characteristics are summarized in [Table 1](#T1){ref-type="table"}, and the studies that provided analyzable data for each outcome and the corresponding heterogeneity are presented in [Table 2](#T2){ref-type="table"}. All studies underwent quality evaluation (Supplemental Table 1 and Supplemental Table 2).

![PRISMA flowchart: summary of the study review and selection process.](ofx11301){#F1}

###### 

Study Characteristics

  Study                         Publication Year   Patients   Episodes   Monotherapy   Regimen                             FEP Dose             Region
  ----------------------------- ------------------ ---------- ---------- ------------- ----------------------------------- -------------------- ------------------
  Aamir \[[@CIT0018]\]          2016               40         40         Yes           FEP vs TZP                          50 mg/kg per 8h      Other (India)
  Aoun \[[@CIT0046]\]           n/a                111        128        Yes           FEP vs CAZ                          2g/8h                Europe
  Biron \[[@CIT0019]\]          1998               380        400        Yes           FEP vs IPM                          2g/12h               Europe
  Bohme \[[@CIT0020]\]          1998               88         102        Yes           FEP vs TZP                          2g/8h                Europe
  Bow \[[@CIT0021]\]            2006               528        528        Yes           FEP vs TZP                          2g/8h                Multiple^a^
  Chandrasekar \[[@CIT0022]\]   2000               276        276        Yes           FEP vs CAZ                          2g/8h                Americas
  Cherif \[[@CIT0023]\]         2004               180        207        Yes           FEP vs IPM                          2g/8h                Europe
  Chuang \[[@CIT0024]\]         2002               95         120        Yes           FEP vs CAZ                          50 mg/kg per 8-12h   Western Pacific
  Corapcioglu \[[@CIT0025]\]    2006               27         50         Yes           FEP vs TZP                          50 mg/kg per 8h      Europe
  Cordonnier \[[@CIT0026]\]     1997               353        353        No            (FEP+AMK) vs (CAZ+AMK)              2g/12h               Europe
  Cornely \[[@CIT0027]\]        2001               207        207        No            (FEP+GEN) vs (CRO+GEN)              2g/8h                Europe
  Erman \[[@CIT0028]\]          2001               208        208        No            (FEP+AMK) vs (CAZ+AMK)              2g/12h               Europe
  Fujita \[[@CIT0029]\]         2016               45         45         Yes           FEP vs MEM                          2g/12h               Western Pacific
  Ghalaut \[[@CIT0030]\]        2007               40         40         Yes           FEP vs CAZ                          1-2g/8h              Other (India)
  Glauser \[[@CIT0047]\]        n/a                281        324        Yes           FEP vs CAZ                          2g/8h                Europe
  Gomez \[[@CIT0031]\]          2010               190        317        No            (FEP+AMK) vs (TZP+AMK)              2g/12h               Europe
  Kebudi \[[@CIT0032]\]         2001               33         63         Yes           FEP vs CAZ                          50 mg/kg per 8h      Europe
  Kutluk \[[@CIT0033]\]         2004               30         49         Yes           FEP vs MEM                          50 mg/kg per 8h      Europe
  Kwon \[[@CIT0034]\]           2008               116        116        Yes           FEP vs PAPM                         2g/12h               Western Pacific
  Mustafa \[[@CIT0035]\]        2001               104        104        Yes           FEP vs CAZ                          50 mg/kg per 8h      Americas
  Nakagawa \[12\]               2013               255        255        Yes           FEP vs PAPM/MEM                     2g/12h               Western Pacific
  Nakane \[11\]                 2015               376        376        Yes           FEP vs CZOP, MEM/IMP                2g/12h               Western Pacific
  Naseem \[[@CIT0036]\]         2011               107        201        Yes           FEP vs TIM                          2g/8h                Other (Pakistan)
  Oguz \[[@CIT0037]\]           2006               37         65         Yes           FEP vs MEM                          50 mg/kg per 8h      Europe
  Raad \[[@CIT0038]\]           2003               251        251        Yes           FEP vs MEM                          2g/8h                Americas
  Ramphal \[[@CIT0039]\]        1996               90         104        Yes           FEP vs CAZ                          2g/8h                Americas
  Sano \[[@CIT0040]\]           2015               53         213        Yes           FEP vs TZP                          100mg/kg per day     Western Pacific
  Sanz \[[@CIT0041]\]           2002               969        984        No            (FEP+AMK) vs (TZP+AMK)              2g/8h                Europe
  Sarashina \[[@CIT0042]\]      2014               64         223        Yes           FEP vs CZOP                         100mg/kg per day     Western Pacific
  Tamura \[[@CIT0043]\]         2002               83         83         Yes           FEP vs carbapenems (PAPM/IMP/MEM)   1-2g/12h             Western Pacific
  Uygun \[[@CIT0044]\]          2009               69         127        Yes           FEP vs TZP                          50 mg/kg per 8h      Europe
  Wang \[[@CIT0045]\]           1999               38         45         Yes           FEP vs CAZ                          2g/8h                Western Pacific

Abbreviations: AMK, amikacin; CAZ, ceftazidime; CRO, ceftriaxone; CZOP, cefozopran; FEP, cefepime; GEN, gentamicin; IMP, imipenem/cilastatin; MEM, meropenem; n/a, not applicable; PAPM, panipenem; TIM, ticarcillin/clavulanate; TZP, piperacillin/tazobactam.

^a^The trial included patients from the United States, Canada, and Australia.

###### 

Number of Studies Providing Data for Each Included Outcome and Corresponding Between-Study Heterogeneity

  Outcome                                                                                                   Studies Reporting on Outcome                                                                                                                                        I^2^
  --------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------
  Clinical efficacy                                                                                         32 \[[@CIT0011], [@CIT0012], [@CIT0018]\]                                                                                                                           0.0%
  Overall mortality (main analysis)                                                                         21 \[[@CIT0011], [@CIT0012], [@CIT0018], [@CIT0024], [@CIT0026], [@CIT0033], [@CIT0034], [@CIT0039], [@CIT0040], [@CIT0044], [@CIT0046], [@CIT0047]\]               0.0%
  Overall mortality (low-dose cefepime monotherapy vs alternative monotherapy)                              6 \[[@CIT0011], [@CIT0012], [@CIT0019], [@CIT0029], [@CIT0034], [@CIT0040]\]                                                                                        0.0%
  Overall mortality (cefepime vs carbapenems)                                                               6 \[[@CIT0011], [@CIT0012], [@CIT0019], [@CIT0029], [@CIT0033], [@CIT0034]\]                                                                                        0.0%
  Overall mortality (main analysis/Cochrane, unpublished data)                                              26 \[[@CIT0011], [@CIT0012], [@CIT0018], [@CIT0026], [@CIT0033], [@CIT0038], [@CIT0043]\]                                                                           0.0%
  Overall mortality (low-dose cefepime monotherapy vs alternative monotherapy/Cochrane, unpublished data)   6 \[[@CIT0011], [@CIT0012], [@CIT0019], [@CIT0029], [@CIT0034], [@CIT0040]\]                                                                                        0.0%
  Overall mortality (cefepime vs carbapenems/Cochrane, unpublished data)                                    9 \[[@CIT0011], [@CIT0012], [@CIT0019], [@CIT0023], [@CIT0029], [@CIT0033], [@CIT0034], [@CIT0038], [@CIT0043]\]                                                    0.0%
  Overall mortality (main analysis/US Food and Drug Administration \[FDA\], unpublished data)               26 \[[@CIT0011], [@CIT0012], [@CIT0018], [@CIT0026], [@CIT0033], [@CIT0038], [@CIT0043]\]                                                                           0.0%
  Overall mortality (low-dose cefepime monotherapy vs alternative monotherapy/FDA, unpublished data)        6 \[[@CIT0011], [@CIT0012], [@CIT0019], [@CIT0029], [@CIT0034], [@CIT0040]\]                                                                                        0.0%
  Overall mortality (cefepime vs carbapenems/FDA, unpublished data)                                         9 \[[@CIT0011], [@CIT0012], [@CIT0019], [@CIT0023], [@CIT0029], [@CIT0033], [@CIT0034], [@CIT0038], [@CIT0043]\]                                                    0.0%
  Infection-specific mortality                                                                              18 \[[@CIT0019], [@CIT0021], [@CIT0026], [@CIT0027], [@CIT0029], [@CIT0031], [@CIT0033], [@CIT0034], [@CIT0036], [@CIT0039], [@CIT0044], [@CIT0045], [@CIT0047]\]   0.0%
  Treatment modification                                                                                    21 \[[@CIT0012], [@CIT0019], [@CIT0028], [@CIT0031], [@CIT0035], [@CIT0039], [@CIT0041], [@CIT0044], [@CIT0045], [@CIT0047]\]                                       0.0%
  Superinfection                                                                                            12 \[[@CIT0022], [@CIT0024], [@CIT0026], [@CIT0028], [@CIT0031], [@CIT0035], [@CIT0038], [@CIT0040], [@CIT0045], [@CIT0047]\]                                       0.0%
  Treatment failure in clinically documented infections                                                     16 \[[@CIT0012], [@CIT0019], [@CIT0023], [@CIT0024], [@CIT0026], [@CIT0027], [@CIT0031], [@CIT0034], [@CIT0041], [@CIT0045]\]                                       0.0%
  Treatment failure in microbiologically documented infections                                              23 \[[@CIT0012], [@CIT0019], [@CIT0026], [@CIT0027], [@CIT0031], [@CIT0034], [@CIT0044]\]                                                                           0.0%
  Adverse events                                                                                            24 \[[@CIT0011], [@CIT0012], [@CIT0018], [@CIT0023], [@CIT0031], [@CIT0034], [@CIT0038], [@CIT0039], [@CIT0041], [@CIT0043], [@CIT0045]\]                           21.5%
  Adverse events (low-dose cefepime monotherapy vs alternative monotherapy)                                 5 \[[@CIT0011], [@CIT0012], [@CIT0019], [@CIT0029], [@CIT0034]\]                                                                                                    27.2%
  Adverse events (cefepime vs carbapenems)                                                                  8 \[[@CIT0011], [@CIT0012], [@CIT0019], [@CIT0023], [@CIT0029], [@CIT0034], [@CIT0038], [@CIT0043]\]                                                                0.0%
  Discontinuation due to adverse events                                                                     15 \[[@CIT0011], [@CIT0019], [@CIT0026], [@CIT0031], [@CIT0035], [@CIT0039], [@CIT0046], [@CIT0047]\]                                                               0.0%
  Discontinuation due to adverse events (high-dose cefepime monotherapy vs alternative monotherapy)         8 \[[@CIT0020], [@CIT0035], [@CIT0039], [@CIT0046], [@CIT0047]\]                                                                                                    0.0%

Clinical Efficacy, Treatment Modification, and Overall Mortality {#s8}
----------------------------------------------------------------

Looking at clinical efficacy, cefepime treatment did not differ significantly compared with other antibiotics (RR = 0.990; 95% CI, 0.943--1.040; *P* = .698). This was the case in both the monotherapy and combination therapy subgroups (RR = 0.988; 95% CI, 0.934--1.045; *P* = .675 and RR = 0.996; 95% CI, 0.905--1.096; *P* = .937, respectively) ([Figure 2](#F2){ref-type="fig"}). Egger's test revealed no evidence of publication bias (ET = −0.480; *P* = .636) and heterogeneity was minimal (I^2^ = 0.0%). Additional subgroup analyses also yielded nonsignificant findings, and the frequency of treatment modification was similar across study arms (Supplemental Results).

![Forest plot of included studies. Relative risk (RR) estimates of the clinical efficacy of cefepime versus comparator regimens. Abbreviation: CI, confidence interval.](ofx11302){#F2}

More importantly, cefepime was associated with increased overall mortality (RR = 1.321; 95% CI, 1.035--1.686; *P* = .025) ([Figure 3](#F3){ref-type="fig"}). This was the case in the monotherapy subgroup (RR = 1.520; 95% CI, 1.138--2.031; *P* = .005) but not in the aminoglycoside combination therapy subgroup (RR = 0.927; 95% CI, 0.584--1.473; *P* = .749). It is interesting to note that cefepime dosage appeared to impact mortality, because trials that used low-dose monotherapy demonstrated increased mortality in the cefepime arm (RR = 1.682; 95% CI, 1.038--2.727; *P* = .035), a result that was based on 6 studies (1225 patients) \[[@CIT0011], [@CIT0012], [@CIT0020], [@CIT0030], [@CIT0035], [@CIT0041]\]. Of note is that only 1 of the aforementioned studies was conducted among pediatric patients \[[@CIT0041]\], and its exclusion did not affect the results (RR = 1.784; 95% CI, 1.088--2.924; *P* = .022).

###### 

Forest plot of included studies. Relative risk (RR) estimates of the overall mortality in the cefepime study arm versus comparator regimens according to our original analysis (A). Additional pooled analyses including supplementary unpublished data reported by the Cochrane meta-analysis (B) and the US Food and Drug Administration meta-analysis (C) are also depicted. Abbreviation: CI, confidence interval
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On the contrary, trials that used high-dose (2 grams/8 hours, 50 mg/kg per 8 hours) regimens were not associated with increased mortality in the cefepime arm (RR = 1.387; 95% CI, 0.958--2.008; *P* = .083 and RR = 1.425; 95% CI, 0.979--2.075; *P* = .064 for all trials and monotherapy, respectively; 10 trials, 1720 patients) \[[@CIT0019], [@CIT0021], [@CIT0028], [@CIT0034], [@CIT0040], [@CIT0045], [@CIT0047], [@CIT0048]\]. It is notable that only 1 study \[[@CIT0028]\] examined combination therapy, whereas the rest were monotherapy trials. The inclusion of previously unpublished data, that were reported for the first time by the Cochrane \[[@CIT0009]\] and FDA \[[@CIT0003]\] studies enabled us to incorporate 4 additional high-dose monotherapy trials \[[@CIT0024], [@CIT0036], [@CIT0039], [@CIT0046]\] into the mortality analysis, for a final population of 2293 patients. More importantly, our findings remained unaffected by the inclusion of these unpublished data (RR = 1.337; 95% CI, 0.962--1.859; *P* = .084 or RR = 1.365; 95% CI, 0.978--1.905; *P* = .068 for all trials and monotherapy, respectively \[Cochrane data \[[@CIT0009]\]\] and RR = 1.313; 95% CI, 0.948--1.818; *P* = .101 or RR = 1.339; 95% CI, 0.964--1.861; *P* = .082 for all trials and monotherapy, respectively \[FDA data \[[@CIT0003]\]\]). It is notable that 4 of these studies provided data on pediatric patients \[[@CIT0019], [@CIT0034], [@CIT0036], [@CIT0045]\], and, after excluding pediatric studies from the analysis, the association between high-dose cefepime administration and overall mortality remained nonsignificant (RR = 1.373; 95% CI, 0.973--1.938; *P* = .072 and RR = 1.405; 95% CI, 0.991--1.992; *P* = .056 for all trials and monotherapy, respectively). Furthermore, 3 trials that used varying cefepime doses (50 mg/kg every 8--12 hours, 1--2 grams/8 hours, and 1--2 grams/12 hours, respectively \[[@CIT0025], [@CIT0031], [@CIT0044]\]) were excluded, because we were unable to ascertain how many patients received high versus low doses.

Furthermore, cefepime monotherapy was associated with increased overall mortality, compared with carbapenem monotherapy (RR = 1.950; 95% CI, 1.177--3.228; *P* = .009), a result that was based on 6 studies (1202 patients) \[[@CIT0011], [@CIT0012], [@CIT0020], [@CIT0030], [@CIT0034], [@CIT0035]\]. However, 5 of the studies used low-dose cefepime regimens \[[@CIT0011], [@CIT0012], [@CIT0020], [@CIT0030], [@CIT0035]\], indicating that this association may stem from the use of low-dose regimens and not from inferiority compared with carbapenems. After including unpublished mortality data from 2 earlier meta-analyses \[[@CIT0003], [@CIT0009]\], the comparison of cefepime versus carbapenems expanded to a total of 9 studies \[[@CIT0011], [@CIT0012], [@CIT0020], [@CIT0024], [@CIT0030], [@CIT0034], [@CIT0035], [@CIT0039], [@CIT0044]\], and 5 of these studies \[[@CIT0011], [@CIT0012], [@CIT0020], [@CIT0030], [@CIT0035]\] used low-dose regimens. More importantly, cefepime monotherapy was again associated with increased overall mortality (RR = 1.690; 95% CI, 1.110--2.572; *P* = .014 and RR = 1.668; 95% CI, 1.089--2.555; *P* = .019, after including data from the Cochrane \[[@CIT0009]\] and FDA \[[@CIT0003]\] meta-analyses, respectively). It is notable that no difference in overall mortality was noted after comparing cefepime with noncarbapenem antibiotics (RR = 1.169; 95% CI, 0.888--1.541; *P* = .266).

Study quality ratings were also shown to impact outcomes, and studies with a low risk of bias in sequence generation (the method by which randomization was performed) supported a positive association between cefepime administration and overall mortality (RR = 1.533; 95% CI, 1.135--2.070; *P* = .005). This was also the case among studies with a low risk of bias in outcome assessment (the process through which treatment efficacy was determined) and allocation concealment (the method by which treatment allocation was concealed) (RR = 1.655; 95% CI, 1.047--2.616; *P* = .031 and RR = 1.798; 95% CI, 1.291--2.504; *P* = .001, respectively). Furthermore, studies with a low risk of other bias also demonstrated increased mortality in the cefepime arm (RR = 1.468; 95% CI, 1.066--2.021; *P* = .019). In contrast, the pooled results of studies that displayed a high or unclear risk of bias in the study areas detailed in the Methods section did not support the association between cefepime administration and overall mortality (the detailed quality assessment of all trials can be viewed in Supplemental Tables 1 and 2, and the results of the performed subanalyses according to study quality are presented in Supplemental Table 3).

Treatment Failure in Patients With Clinically and Microbiologically Documented Infections, Infection-Specific Mortality, and Superinfections {#s9}
--------------------------------------------------------------------------------------------------------------------------------------------

Treatment failure among patients with clinically documented infections was significantly more common with cefepime therapy (RR = 1.143; 95% CI, 1.004--1.300; *P* = .043) (16 trials, reporting on 355 cefepime-treated infections vs 384 infections treated with other antibiotics \[[@CIT0012], [@CIT0020], [@CIT0024], [@CIT0025], [@CIT0027], [@CIT0028], [@CIT0032], [@CIT0035], [@CIT0042], [@CIT0046]\]). However, additional subanalyses yielded nonsignificant findings (Supplemental Results). It is interesting to note that the incidence of treatment failure in microbiologically documented infections (23 trials, reporting on 455 cefepime-treated infections vs 420 infections treated with other antibiotics \[[@CIT0012], [@CIT0020], [@CIT0027], [@CIT0028], [@CIT0032], [@CIT0035], [@CIT0045]\]) was similar across study arms (Supplemental Results). Furthermore, the occurrence of superinfections (12 trials, reporting on 174 vs 161 superinfections in the cefepime and comparator study arms, respectively \[[@CIT0023], [@CIT0025], [@CIT0027], [@CIT0029], [@CIT0032], [@CIT0036], [@CIT0039], [@CIT0041], [@CIT0046], [@CIT0048]\]) was not significantly different in the cefepime arm (Supplemental Results). Finally, infection-specific mortality (18 trials, 4007 patients \[[@CIT0020], [@CIT0022], [@CIT0027], [@CIT0028], [@CIT0030], [@CIT0032], [@CIT0034], [@CIT0035], [@CIT0037], [@CIT0040], [@CIT0045], [@CIT0046], [@CIT0048]\]) was similar in patients treated with cefepime or other antibiotics (Supplemental Results).

Incidence of Adverse Events and Toxicity-Related Treatment Discontinuation {#s10}
--------------------------------------------------------------------------

Next, we investigated whether toxicity was also related to cefepime dose. Indeed, we found that the overall frequency of adverse events was similar among patients treated with cefepime or other antibiotics (RR = 0.964; 95% CI, 0.906--1.026; *P* = .246 and RR = 0.953; 95% CI, 0.899--1.011; *P* = .112 for all studies and cefepime monotherapy, respectively) but significantly lower among patients treated with low-dose cefepime monotherapy (RR = 0.681; 95% CI, 0.510--0.910; *P* = .009). In contrast, in trials using high-dose cefepime monotherapy, the frequency of adverse events was similar in both study arms (RR = 0.998; 95% CI, 0.945--1.054; *P* = .946). Toxicity-related treatment discontinuation was more frequent among patients treated with cefepime monotherapy (RR = 1.566; 95% CI, 1.094--2.241; *P* = .014). More importantly, cefepime dosing impacted the likelihood of treatment discontinuation. Specifically, a statistically significant increase in treatment discontinuation was noted among patients receiving a high-dose regimen (RR = 1.535; 95% CI, 1.047--2.249; *P* = .028 and RR = 1.558; 95% CI, 1.055--2.302; *P* = .026 for all studies and monotherapy, respectively) but not among patients receiving a low-dose regimen (RR = 0.913; 95% CI, 0.525--1.587; *P* = .746 and RR = 1.494; 95% CI, 0.579--3.856; *P* = .407 for all studies and monotherapy, respectively). Additional information on the adverse events that led to treatment discontinuation is provided in Supplemental Results.

DISCUSSION {#s11}
==========

Much controversy has surrounded the use of cefepime for febrile neutropenia \[[@CIT0003], [@CIT0009]\], yet no satisfactory interpretation of the reported association of cefepime with increased mortality has been provided to date \[[@CIT0007]\]. Moreover, even though the FDA recommends a dose of 2 grams/8 hours or 50 mg/kg per 8 hours for this indication \[[@CIT0003], [@CIT0049]\], lower doses are used in practice with considerable frequency \[[@CIT0003], [@CIT0006], [@CIT0010]\]. In this context, the present study aimed to reassess the safety and efficacy of cefepime for this indication, and we detected increased overall mortality and reduced treatment efficacy in clinically documented infections in the cefepime arm and increased toxicity associated with high-dose regimens. More importantly, cefepime dosage appears to have a previously underappreciated impact on outcomes, because trials that used low-dose cefepime monotherapy demonstrated significantly increased overall mortality in the cefepime arm, unlike studies that used high-dose cefepime regimens. It is interesting to note that increased toxicity was observed with high-dose cefepime regimens.

In line with previous studies, cefepime was associated with increased mortality \[[@CIT0007]\]. The validity of this finding is supported by the fact that the association was more pronounced among studies with a lower risk of bias in study design and by the inferior efficacy of cefepime in clinically documented infections. In light of these results, it might seem paradoxical that cefepime demonstrated similar clinical efficacy with other antibiotics. However, clinical efficacy is a less reliable measure of treatment effectiveness than mortality, because definitions of treatment success vary across studies, and treatment modification may stem from considerations other than treatment failure. As such, consistent with previous reports \[[@CIT0007]\], the overall clinical efficacy of cefepime was similar to that of alternative regimens.

The impact of cefepime dosing on mortality is particularly important, because the advantages and disadvantages of high-dose versus low-dose regimens have not been studied thoroughly. Specifically, although the FDA recommends the use of high-dose regimens \[[@CIT0049]\], some reports advocate the use of lower doses, despite the lack of conclusive evidence of therapeutic equivalence \[[@CIT0006], [@CIT0010]\]. Low-dose cefepime regimens have a lower probability of achieving the target serum concentrations necessary for eradicating resistant pathogens, such as *Pseudomonas aeruginosa* \[[@CIT0050]\], and may, consequently, display reduced in vivo efficacy. However, it should be noted that our analysis is inadequately powered to conclusively prove the inferiority of low-dose compared with high-dose cefepime regimens. Specifically, the 95% CIs of the low-dose cefepime versus comparators and high-dose cefepime versus comparators subanalyses overlap. As such, the noninferiority of low-dose regimens compared with high-dose regimens cannot be conclusively rejected by the present analysis. Nevertheless, the disproportionate impact of a small number of low-dose trials on mortality and the existence of pharmacokinetic data that question the efficacy of low-dose cefepime regimens strongly support the need to formally assess the equivalence of different dosing recommendations.

It is interesting to note that cefepime-related toxicity was also shown to be dose dependent. In particular, a significantly increased rate of toxicity-related treatment discontinuation was noted in the cefepime arm, an effect driven by trials that used high-dose regimens. This was not the case with low-dose cefepime monotherapy, which was associated with significantly fewer adverse events and similar rates of treatment discontinuation, compared with alternative monotherapy. In turn, it is possible that an increased rate of toxicity-related treatment discontinuation may impact outcomes either directly, by causing a "break" in effective antimicrobial coverage during treatment modification, or indirectly, by serving as a proxy for an increased rate of severe toxicity in the cefepime arm, as has been previously hypothesized \[[@CIT0008]\]. Taken together, these findings suggest that higher doses may result in enhanced efficacy but at the cost of increased toxicity. In turn, increased toxicity may help to explain why a nonsignificant trend towards increased mortality was sometimes observed in the cefepime arm, even in studies that used high-dose regimens. Although it is difficult to quantify the relative impact of toxicity and efficacy on outcomes, it is important to note that high-dose regimens may also have inherent limitations. As a result, longitudinal monitoring of adverse events will prove essential to better characterizing the toxicity profile of cefepime.

Although a pattern of dose-dependent efficacy may, by and large, explain the association of cefepime with increased mortality, possible inferiority compared with carbapenem therapy may also contribute to these findings. As detailed above, cefepime was associated with increased overall mortality in comparison with carbapenem-based regimens, and no similar association was detected when comparing cefepime with other antibiotics, thus suggesting that cefepime may be specifically inferior to carbapenem therapy. Previous meta-analyses failed to detect significant differences in mortality after comparing cefepime with other antibiotics, including carbapenems \[[@CIT0007]\]. In turn, this may be explained by changing antibiotic resistance patterns over time. Specifically, carbapenems are known to be more efficacious than other β-lactams in the treatment of extended spectrum β-lactamase (ESBL)-producing pathogens \[[@CIT0053]\], and 2 newly published trials which demonstrated increased mortality in cefepime-treated versus carbapenem-treated patients were conducted in Japan \[[@CIT0011], [@CIT0012]\], where an increase in ESBL prevalence has been reported \[[@CIT0054]\]. However, it should be noted that the majority of trials comparing cefepime with carbapenem therapy also used low-dose cefepime regimens \[[@CIT0011], [@CIT0012], [@CIT0020], [@CIT0030], [@CIT0035]\], and, consequently, cefepime dosing may have confounded this association, or low-dose cefepime monotherapy may be at a particular disadvantage, compared with carbapenems.

Regarding study limitations, the present meta-analysis is restricted by the quality and quantity of the data provided by the included studies. For example, information on secondary outcomes was occasionally missing from the published studies, thus increasing the likelihood of a type II error in the respective analyses. Unpublished mortality data provided by the FDA \[[@CIT0003]\] and Cochrane \[[@CIT0009]\] studies were used in an attempt to mitigate this limitation. Furthermore, we decided not to include unpublished conference proceedings in the present study, because conference proceedings rarely report details on trial methodology, which are necessary to evaluate study quality. To assess whether this decision influenced our results, we performed a subanalysis that incorporated data from unpublished conference proceedings, reported in the most recent Cochrane review \[[@CIT0009]\], and our results were unaffected (Supplemental Results). In addition, although the present meta-analysis incorporated more studies than previous reports, it should be noted that many factors (study quality, patient characteristics, etc) could confound our results, and our capacity to adjust for them while maintaining adequate statistical power is extremely limited, particularly in subanalyses with a small number of included studies. Furthermore, low statistical power complicates the interpretation of subgroup analyses with respect to the impact of cefepime dosing on outcomes. Specifically, despite the significant association of cefepime with mortality in trials that used low-dose regimens, and the lack of such an association among trials using high-dose regimens, the corresponding 95% CIs overlap. The latter finding probably stems from the reduction in statistical power that accompanies division of the patient population into subgroups. In turn, an accurate assessment of the relative efficacy of high-dose versus low-dose cefepime regimens is difficult to perform.

CONCLUSIONS {#s12}
===========

In conclusion, the present meta-analysis not only confirmed the association of cefepime therapy with increased overall mortality among patients with febrile neutropenia, but it also identified potential underlying associations. More specifically, cefepime dosage may exert an important impact on outcomes, because low-dose cefepime monotherapy was associated with decreased toxicity, at the expense of increased overall mortality. Possible inferiority compared with carbapenems, reduced efficacy in clinically documented infections, and higher rates of toxicity-related treatment discontinuation may also contribute to this association. More importantly, our results suggest that increased mortality may be limited to specific treatment settings and dosing regimens. Although our findings require confirmation by future trials, the present study suggests that outcomes may be optimized by adjusting cefepime dosing recommendations and treatment indications, rather than by discontinuing the use of this important antibiotic.
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Supplementary materials are available at *Open Forum Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.
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